articleTop 1% cited
Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
Annals of Surgical Oncology · 2009 · Vol. 16(7) · pp. 1727–1733
Mark P. Callery✉(Beth Israel Deaconess Medical Center)Kenneth J. Chang(University of California System)Elliot K. Fishman(Johns Hopkins University)Mark S. Talamonti(Johns Hopkins University)L. William Traverso(Virginia Mason Medical Center)David C. Linehan(Washington University in St. Louis)
Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsRenal cell carcinoma treatmentMedicineSurgical oncologyStatement (logic)General surgeryPancreatic cancerMEDLINEOncologyInternal medicineCancer
MeSH terms
AdenocarcinomaBiopsyHumansNeoplasm StagingPancreasPancreatectomyPancreatic NeoplasmsPreoperative Care
Citations
893
FWCI
12.11
field-weighted impact
References
39
Percentile
99%
vs. same field & year
Citations per year
Cited by
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2015 · 1,308 citations
Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design
Annals of Surgical Oncology · 2013 · 337 citations
References
Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT.
American Journal of Roentgenology · 1997 · 547 citations
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Annals of Surgical Oncology · 2006 · 872 citations
Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA
Gastrointestinal Endoscopy · 2003 · 424 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.